Piezzo, M.; D’Aniello, R.; Avallone, I.; Barba, B.; Cianniello, D.; Cocco, S.; D’Avino, A.; Di Gioia, G.; Di Lauro, V.; Fusco, G.;
et al. Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center. Pharmaceutics 2021, 13, 684.
https://doi.org/10.3390/pharmaceutics13050684
AMA Style
Piezzo M, D’Aniello R, Avallone I, Barba B, Cianniello D, Cocco S, D’Avino A, Di Gioia G, Di Lauro V, Fusco G,
et al. Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center. Pharmaceutics. 2021; 13(5):684.
https://doi.org/10.3390/pharmaceutics13050684
Chicago/Turabian Style
Piezzo, Michela, Roberta D’Aniello, Ilaria Avallone, Bruno Barba, Daniela Cianniello, Stefania Cocco, Antonio D’Avino, Germira Di Gioia, Vincenzo Di Lauro, Giuseppina Fusco,
and et al. 2021. "Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center" Pharmaceutics 13, no. 5: 684.
https://doi.org/10.3390/pharmaceutics13050684
APA Style
Piezzo, M., D’Aniello, R., Avallone, I., Barba, B., Cianniello, D., Cocco, S., D’Avino, A., Di Gioia, G., Di Lauro, V., Fusco, G., Piscitelli, R., von Arx, C., De Laurentiis, M., & Maiolino, P.
(2021). Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center. Pharmaceutics, 13(5), 684.
https://doi.org/10.3390/pharmaceutics13050684
